Trump announces trade deal with EU following months of negotiations
LONDON - Avacta Group (AIM:AVCT) announced Thursday a new partial response in a patient with salivary gland cancer during the dose expansion phase of its FAP-Dox (AVA6000) Phase 1b trial.
The response was observed in a 69-year-old male with metastatic salivary gland cancer whose tumor diameter was reduced by almost 50% at the first scan. The patient had previously undergone surgery and radiation but had not received systemic therapy.
This follows earlier data presented at the American Association of Cancer Research annual meeting in April 2025, which showed one confirmed partial response and multiple minor responses in the Phase 1a cohort, with a disease control rate of 91%. The median progression-free survival had not been reached at the time of data cutoff.
Metastatic salivary gland cancer currently has no preferred standard therapy, representing a significant unmet medical need in oncology.
"We are thrilled to see the antitumor activity of FAP-Dox in this disease with no preferred standard therapy," said Christina Coughlin, CEO of Avacta. "The high unmet need in this indication underscores the potential for FAP-Dox to have a meaningful impact to patients."
Avacta plans to publish final data from the AVA6000 Phase 1a trial in the second half of 2025 and will provide a business update at its Annual General Meeting on July 2, 2025.
The company is developing targeted oncology drugs and made this announcement based on its ongoing clinical trial results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.